VRML - バ―ミリオン (Vermillion Inc.) バ―ミリオン

 VRMLのチャート


 VRMLの企業情報

symbol VRML
会社名 Vermillion Inc (バ―ミリオン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Vermillion Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to in addition to a physician's clinical assessment of a woman with a pelvic mass identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2 500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.   バ―ミリオンは、米国の診断検査プロバイダ―。主に婦人科癌および関連疾患の患者向けの医療検査の発見、開発、商品化に従事する。主要製品OVA1は、ソフトウェアアルゴリズム及び血液検査を統合卵巣癌試験システムで、悪性卵巣腫瘍の識別検査。本社はテキサス州オ―スティン。   Vermillion Inc is engaged in discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases.
本社所在地 12117 Bee Caves Road Building Three Suite 100 Austin TX 78738 USA
代表者氏名 James T. LaFrance James T. LaFrance
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 512-519-0400
設立年月日 34304
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 40人
url www.vermillion.com
nasdaq_url https://www.nasdaq.com/symbol/vrml
adr_tso
EBITDA EBITDA(百万ドル) -10.55000
終値(lastsale) 0.64
時価総額(marketcap) 48175520.64
時価総額 時価総額(百万ドル) 35.76280
売上高 売上高(百万ドル) 2.85400
企業価値(EV) 企業価値(EV)(百万ドル) 23.20180
当期純利益 当期純利益(百万ドル) -12.30500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vermillion Inc. revenues decreased 16% to $1.4M. Net loss increased 17% to $5.9M. Revenues reflect Product decrease of 19% to $1.2M. Higher net loss reflects Sales and Marketing - other increase of 32% to $2.6M (expense) General and administrative increase of 3% to $2.2M (expense) Other income (expense) net increase of 56% to $14K (expense).

 VRMLのテクニカル分析


 VRMLのニュース

   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019-05-14
Vermillion, Inc. (VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri President and Chief Executive Officer Bob Beechey Chief Financial Officer Chris Goulart Senior Vice President-Commercial Operations …
   Vermillion reports Q1 results  2019-05-14
Vermillion (NASDAQ: VRML ): Q1 GAAP EPS of -$0.05. More news on: Vermillion, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019-05-14
Vermillion, Inc. (VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri President and Chief Executive Officer Bob Beechey Chief Financial Officer Chris Goulart Senior Vice President-Commercial Operations …
   Vermillion reports Q1 results  2019-05-14
Vermillion (NASDAQ: VRML ): Q1 GAAP EPS of -$0.05. More news on: Vermillion, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バ―ミリオン VRML Vermillion Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)